
Consumer Health Data Privacy Policy
STAAR SURGICAL CONSUMER HEALTH DATA PRIVACY POLICY
Last Updated: October 30, 2026
INTRODUCTION
STAAR Surgical Company and our global subsidiaries and affiliates (collectively, “STAAR,” “we,” “us,” and “our”) are committed to respecting your privacy. This Consumer Health Data Privacy Policy supplements the STAAR Surgical Privacy Policy and applies to personal data defined as “consumer health data” subject to the Washington State My Health My Data Act.
CONSUMER HEALTH DATA COLLECTED
Consumer health data means personal information that is linked or reasonably linkable to a consumer and that identifies the consumer’s past, present, or future physical or mental health status. The consumer health data we collect depends on the context of your interaction with us. Examples of consumer health data we may collect in the course of providing our services include information about an individual’s:
- health conditions, treatment, diseases, or diagnoses (e.g., vision disorders);
- medical interventions;
- use or purchase of medications or prescribed medications;
- measurements of health information (e.g., eye measurements);
- diagnoses or diagnostic testing, treatment, or medication; or
- information that could identify an individual seeking health care services or information.
SOURCES OF CONSUMER HEALTH DATA
We collect consumer health data from the following sources:
- directly from you when you interact with us or use our services;
- automatically through cookies and other tracking technologies that reveal your interest in our services; or
- from third parties such as healthcare providers who provide health data to us pursuant to your authorization.
PURPOSES FOR COLLECTION AND USE
Our collection of consumer health data is necessary for the provision of our services. In addition, we may use consumer health data to compile analytics, improve our services, comply with legal and regulatory obligations, for any other purpose with your consent, or otherwise as described in the STAAR Surgical Privacy Policy.
DISCLOSURE OF CONSUMER HEALTH DATA
In addition to sharing consumer health data with our service providers, we may share consumer health data with the following third parties:
- Our affiliates listed in Annex I below.
- Certain third parties with your consent or at your direction. These parties may include healthcare providers.
- Other third parties to protect our rights, defend or pursue a legal claim, or investigate or prosecute illegal activities.
- Government or judicial authorities or agencies to comply with a subpoena, court order, governmental inquiry, legal process, legal obligation, or to protect the rights, property, or safety of other users or the public, including mandatory disclosures to public health authorities or adverse event reporting to regulatory agencies.
We may also share consumer health data with a successor entity or purchaser upon a merger, consolidation, or other corporate reorganization in which we participate, or pursuant to a financing arrangement.
YOUR RIGHTS
Washington residents have the following rights with respect to their consumer health data, subject to certain exceptions:
- the right to confirm whether we process your consumer health data, and to access and receive a copy of your consumer health data;
- the right to a list of all third parties and affiliates with whom we have shared or sold your consumer health data and an email address or other online mechanism that you can use to contact each third party;
- the right to delete your consumer health data; and
- the right to withdraw consent to the collection, sharing, or selling of consumer health data.
You can submit a request to exercise these rights using any of the mechanisms listed in the “Contact Information” section below. Depending on the type of request, we may need to verify your request before we can fulfill it. Please note that certain exceptions may apply to these rights (e.g., we may be unable to honor a request to delete if it conflicts with a legal obligation to retain data). Finally, please review the STAAR Surgical Privacy Policy for additional rights and choices you may have with respect to your personal data more generally.
You have the right to appeal any decisions we make in response to a rights request. If your appeal is unsuccessful, you can raise a concern or lodge a complaint with the Washington State Attorney General at www.atg.wa.gov/file-complaint.
CHANGES TO THIS POLICY
We may revise this policy from time to time. When we make changes to this policy, we will post the updated version on our website and indicate the date the policy was last updated. We encourage you to review this policy periodically to check for any updates.
CONTACT INFORMATION
If you have questions or concerns regarding this policy or wish to exercise your privacy rights, please contact us at:
STAAR Surgical Company
25510 Commercentre Drive, Ste. 200, Lake Forest, California 92630, USA
Phone: 1.626.303.7902
Email: PrivacyOffice@staar.com
SUPPLEMENT TO CONSUMER HEALTH DATA PRIVACY POLICY FOR NEVADA CONSUMERS
This supplement to our Consumer Health Data Privacy Policy applies to Nevada residents for purposes of providing additional disclosures required by Nevada’s consumer health data privacy law (Nevada Senate Bill 370).
The foregoing consumer health data disclosures and rights also apply to Nevada residents. In addition, Nevada residents also have the right to review and amend any consumer health data we maintain about them. Nevada residents can escalate unsuccessful appeals of consumer rights requests to the Nevada attorney general at https://ag.nv.gov/Complaints/CSU_Complaints___FAQ/. Third parties may collect consumer health data over time and across different websites when you use our websites.
ANNEX I: LIST OF RELEVANT STAAR ENTITIES
- STAAR Surgical Company (Delaware, United States)
- STAAR Surgical AG (Nidau, Switzerland)
Viktig sikkerhetsinformasjon
ICL er utviklet for korreksjon/reduksjon av nærsynthet hos pasienter mellom 21 og 60 år, og for pasienter over 21 år som tidligere er behandlet med en intraokulær linse, i området -0,5 D til -20,0 D, med eller uten astigmatisme opptil 6,0 D. Den er også beregnet på korreksjon/reduksjon av langsynthet hos pasienter mellom 21 og 45 år, og for pasienter over 21 år som har blitt behandlet med en intraokulær linse, i området +0,5 D til +16,0 D, med eller uten astigmatisme opptil 6,0 D. For at kirurgen din skal kunne bruke en ICL med riktig styrke for øyet ditt, bør nærsyntheten, langsyntheten og astigmatismen din være stabile i minst ett år før operasjonen. ICL-operasjon kan forbedre synet ditt uten bruk av briller eller kontaktlinser. Siden både nærsynt- og langsynt-ICL korrigerer for avstandssyn, eliminerer det ikke behovet for lesebriller hos personer med presbyopi. Du kan trenge dem senere, selv om du aldri har brukt dem før. ICL er et alternativ til andre refraktive operasjoner, inkludert laserassistert in situ keratomileusis (LASIK), fotorefraktiv keratektomi (PRK), snittbaserte kirurgier, eller andre metoder for synskorreksjon som kontaktlinser og briller. Innsetting av en ICL er et kirurgisk inngrep og medfører potensielt alvorlige risikoer. Følgende komplikasjoner/bivirkninger er rapportert i forbindelse med refraktiv kirurgi generelt: behov for ytterligere operasjoner, grå stær, tap av best korrigerte syn, økt trykk i øyet, tap av celler på hornhinneendotelet, konjunktival irritasjon, akutt hornhinnehevelse, vedvarende hornhinnehevelse, endoftalmitt (alvorlig øyeinfeksjon), betydelig blending og/eller lysringer, hyphema (blod i øyet), hypopyon (puss i øyet), øyeinfeksjon, ICL-dislokasjon, makulaødem, ikke-reaktiv pupill, pupilleblokkglaukom, alvorlig øyebetennelse, iritt, uveitt, tap av glasslegemet og behov for hornhinnetransplantasjon. Før du vurderer ICL-operasjon bør du ha en grundig øyeundersøkelse og diskutere med øyelegen din om operasjonen, spesielt fordeler, risikoer og mulige komplikasjoner. Du bør også diskutere hvor lang tid helbredelsen etter operasjonen vil ta.
Locale Switcher
Latin America
Referanser
- Ganesh S, Brar S, Pawar A. Matched population comparison of visual outcomes and patient satisfaction between 3 modalities for the correction of low to moderate myopic astigmatism. Clin Ophthalmol. 2017;11:1253-63.
- Zhang H, Deng Y, Ma K, Yin H, Tang J. Analysis on the changes of objective indicators of dry eye after implantable collamer lens (ICL) implantation surgery. Graefes Arch Clin Exp Ophthalmol. 2024 Jul;262(7):2321-2328.
- Packer M. The Implantable Collamer Lens with a central port: review of the literature. Clin Ophthalmol. 2018;12:2427-2438.
- Martínez-Plaza E, López-Miguel A, López-De La Rosa A, et al. Effect of the EVO+ Visian Phakic Implantable Collamer Lens on Visual Performance and Quality of Vision and Life, Am J Ophthalmol 2021;226: 117-125.
- Packer M. Evaluation of the EVO/EVO+ Sphere and Toric Visian ICL: Six Month Results from the United States Food and Drug Administration Clinical Trial. Clin Ophthalmol. 2022;16:1541-53.
- Shoja MR, Besharati MR. Dry eye after LASIK for myopia: Incidence and risk factors. Eur J Ophthalmol. 2007;17(1):1-6.
- Lee JB, Ryu CH, Kim JH, et al. Comparison of tear secretion and tear film instability after photorefractive keratectomy and laser in situ keratomileusis. Journal of Cataract and Refractive Surgery. 2000;26(9):1326-1331.
- Albo C, Nasser T, Szynkarski DT, Nguyen N, Mueller B, Libfraind L, Parkhurst G. A Comprehensive Retrospective Analysis of EVO/EVO+ Implantable Collamer Lens: Evaluating Refractive Outcomes in the Largest Single Center Study of ICL Patients in the United States. Clin Ophthalmol. 2024 Jan 9;18:69-78.
- Parkhurst GD. A prospective comparison of phakic collamer lenses and wavefront-optimized laser-assisted in situ keratomileusis for correction of myopia. Clin Ophthalmol. 2016;10:1209-1215.